Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Open in API
Filings indexed 341 across all filing types
Latest filing 2022-08-17 Interim / Quarterly Rep…
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport andra kvartalet 2022' (Interim Report for the second quarter of 2022) for Inify Laboratories AB. It contains detailed sections on business development, financial performance, cash flow, risk factors, and accounting principles for the specified period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2022
2022-08-17 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the second quarter 2022' and contains detailed sections on company development, financial development, cash-flow, and condensed financial statements prepared in accordance with the Swedish Annual Accounts Act. It provides substantive financial analysis and business updates for the specified period, fitting the definition of an Interim/Quarterly Report (IR). Q2 2022
2022-08-17 English
Inify's first ultramodern laboratory on track
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport andra kvartalet 2022' (Interim Report for the second quarter of 2022) for Inify Laboratories AB. It contains detailed sections on financial development, cash flow, balance sheet items, accounting principles, and management commentary regarding the company's operations and outlook. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2022
2022-08-17 Swedish
Inifys første ultramoderne laboratorium i rute
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the second quarter 2022' and contains detailed financial development, cash-flow, and management commentary. It provides substantive financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full content of the report itself. Q2 2022
2022-08-17 English
Inify's first ultramodern laboratory on track
Regulatory Filings Classification · 99% confidence The document is a short press release dated August 17, 2022, detailing operational updates (laboratory construction, IT system development), management changes (new CMO joining), and recent funding activities (NOK 150 million private placement in Q2). It is not a comprehensive annual report (10-K), an interim report (IR), or a formal earnings release (ER) which typically contains detailed financial tables. It is an announcement of business progress and financing. Since it discusses funding and general business updates without fitting neatly into specific categories like M&A (TAR) or Director's Dealing (DIRS), and it is not a formal regulatory filing announcement (RPA/RNS) about a major report, the most appropriate category is a general business update or financing announcement. Given the options, 'Capital/Financing Update' (CAP) covers the fundraising aspect, but the document is broader, covering operations and personnel. However, since it is a news release announcing operational milestones and recent financing, and it is short, it functions as a general business update. If a specific 'Business Update' category existed, it would fit there. Among the provided codes, 'Regulatory Filings' (RNS) is the fallback for miscellaneous announcements. Given the content is a press release about operational progress and recent financing, and it is not a formal SEC filing, RNS is the best fit as a general regulatory/news announcement, although CAP is partially relevant due to the funding mention. Given the context of financial reporting databases, short operational updates often fall under RNS if they don't trigger a specific financial report code. I will classify it as RNS as it is a general news release.
2022-08-17 English
Inifys første ultramoderne laboratorium i rute
Regulatory Filings Classification · 100% confidence The document is a press release dated August 17, 2022, detailing operational updates (building a new lab, IT system development), management changes (hiring a CMO), and recent financing activities (NOK 150 million raised in Q2). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It announces business progress and capital structure updates. Since it discusses raising capital (NOK 150 million in Q2) and provides general business updates, it fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a mandatory disclosure. Given the specific mention of securing financing and operational milestones, 'CAP' is a strong candidate, but since it's a general news announcement about operations and financing, and not a formal prospectus or detailed financing document, 'RNS' (Regulatory Filings/General Announcement) is often the appropriate category for such corporate news releases that don't fit the highly specific financial report codes. However, the content heavily features financing and operational progress, which are often disclosed via RNS. Given the options, and that it's a general corporate update announcement, RNS is the most suitable fallback for non-standardized news releases, although CAP is relevant due to the financing mention. I will classify it as RNS as it reads like a general regulatory announcement/press release.
2022-08-17 Norwegian

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.